skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: {sup 106}Ruthenium Plaque Therapy (RPT) for Retinoblastoma

Journal Article · · International Journal of Radiation Oncology, Biology and Physics
 [1];  [2];  [1];  [3]; ; ; ; ; ; ; ; ;  [1]; ;  [4];  [1]
  1. Department of Radiation Oncology, National Cancer Center Hospital, Tokyo (Japan)
  2. Department of Ophthalmic Oncology, National Cancer Center Hospital, Tokyo (Japan)
  3. Department of Diagnostic Radiology and Oncology, Head and Neck Reconstruction Division, Graduate School, Tokyo Medical and Dental University, Tokyo (Japan)
  4. Department of Radiology, University of Tokyo Hospital, Tokyo (Japan)

Purpose: To evaluate the effectiveness of episcleral {sup 106}ruthenium plaque therapy (RPT) in the management of retinoblastoma. Methods and Materials: One hundred one RPTs were retrospectively analyzed that were performed in 90 eyes of 85 patients with retinoblastoma at National Cancer Center Hospital between 1998 and 2008. Each RPT had a corresponding tumor and 101 tumors were considered in the analysis of local control. Median follow-up length was 72.8 months. Median patient age at the RPT was 28 months. Median prescribed doses at reference depth and outer surface of the sclera were 47.4 Gy and 162.3 Gy, respectively. Results: Local control rate (LCR) and ocular retention rate (ORR) at 2 years were 33.7% and 58.7%, respectively. Unilateral disease, International Classification of Retinoblastoma group C or more advanced at the first presentation or at the time of RPT, vitreous and/or subretinal seeding, tumor size greater than 5 disc diameter (DD), reference depth greater than 5 mm, dose rate at reference depth lower than 0.7 Gy/hour, dose at the reference depth lower than 35 Gy, and (biologically effective dose with an {alpha}/{beta} ratio of 10 Gy) at the reference depth lower than 40 Gy{sub 10} were associated with unfavorable LCR. Two patients died of metastatic disease. Radiation complications included retinal detachment in 12 eyes (13.3%), proliferative retinopathy in 6 (6.7%), rubeosis iris in 2 (2.2%), and posterior subcapsular cataract in 23 (25.6%). Conclusion: RPT is an effective eye-preserving treatment for retinoblastoma.

OSTI ID:
22149441
Journal Information:
International Journal of Radiation Oncology, Biology and Physics, Vol. 84, Issue 1; Other Information: Copyright (c) 2012 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
Country of Publication:
United States
Language:
English

Similar Records

Cobalt60 plaques in recurrent retinoblastoma
Journal Article · Thu Aug 01 00:00:00 EDT 1991 · International Journal of Radiation Oncology, Biology and Physics; (United States) · OSTI ID:22149441

External beam irradiation for retinoblastoma: patterns of failure and dose-response analysis
Journal Article · Wed Mar 01 00:00:00 EST 1989 · Int. J. Radiat. Oncol., Biol. Phys.; (United States) · OSTI ID:22149441

{beta}-Ray brachytherapy with {sup 106}Ru plaques for retinoblastoma
Journal Article · Sat Jul 15 00:00:00 EDT 2006 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:22149441